We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App





GenScript Demonstrates High-Throughput Measurement of Neutralization Antibody Titers in Serum Samples from SARS-CoV-2 Infected Patients

By LabMedica International staff writers
Posted on 15 Dec 2020
Print article
Image: cPass Surrogate Virus Neutralization Test (Photo courtesy of GenScript USA Inc.)
Image: cPass Surrogate Virus Neutralization Test (Photo courtesy of GenScript USA Inc.)
GenScript USA Inc. (Piscataway, NJ, USA) presented its newly available assay termed cPass Surrogate Virus Neutralization Test (cPassTM sVNT) at the all virtual 2020 AACC Annual Scientific Meeting held on December 13-17.

The assay permits the qualitative and quantitative evaluation of neutralizing antibodies in a simple, cost-effective, and high-throughput test. With the oncoming SARS-CoV-2 vaccination programs soon to be initiated globally, many questions have arisen concerning the efficacy and duration of protection. The focus on a subset of immune response antibodies that block and effectively neutralize the interaction between the virus and host cells has become a key measure of vaccine efficacy. However, their measurement is challenging with the pre-existing live cell neutralization tests that are considered gold standard.

Samples from SARS-CoV-2 recovered individuals exhibited differences up to 400-fold in neutralizing antibody titers demonstrating the practical application of cPass sVNT to assess strength of immune response between both infected and vaccinated individuals; level of protection against re-infection, and duration of protection post-infection/vaccination. cPass sVNT detects circulating neutralizing antibodies against SARS-CoV-2 that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor. This kit would be instrumental in vaccine and therapeutic development as it is suitable for all antibody isotypes and can be used to determine neutralizing antibodies in animal models without modification. The kit will also help in current COVID-19 investigations of sero-prevalence, assessment of herd immunity, longevity of protective immunity, efficacy of different vaccine candidates as well as tracking infection in animals.

Related Links:
GenScript USA Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.